<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335591</url>
  </required_header>
  <id_info>
    <org_study_id>19-OBE2109-006</org_study_id>
    <nct_id>NCT04335591</nct_id>
  </id_info>
  <brief_title>Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)</brief_title>
  <official_title>A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this extension study is to assess the maintenance of efficacy of&#xD;
      linzagolix administered orally once daily for up to an additional 6 months (for up to 12&#xD;
      months of treatment in total) in women who have already completed 6 months of linzagolix&#xD;
      treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5&#xD;
      mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women&#xD;
      with surgically confirmed endometriosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind study. Subjects who have completed the&#xD;
      6-month Treatment Period in 18-OBE2109-003 - Edelweiss 3 study (herein referred to as main&#xD;
      study) will be invited to enter the present extension study. Month 6 visit of the main study&#xD;
      is a decision point for Subjects to either end treatment and enter a post-treatment follow up&#xD;
      (part of the main study), or to opt for a 6-month treatment extension.&#xD;
&#xD;
      All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200&#xD;
      mg combined with ABT for 6 months. Subjects who received placebo during the main study will&#xD;
      be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with&#xD;
      ABT. Subjects who received active treatment during the main study will continue with the same&#xD;
      treatment. Double-dummy design will be used in order to maintain the blinding of the study.&#xD;
&#xD;
      After end of treatment in the extension study (6-month treatment period: from Month 6 to&#xD;
      Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no&#xD;
      investigational medicinal product (IMP) or - for subjects willing to continue treatment - a&#xD;
      second extension study will be proposed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change at Month 12 from baseline in the mean daily assessment of dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change at Month 12 from baseline in the mean daily assessment of non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyschezia</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dyschezia measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pelvic Pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in overall pelvic pain measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference of pain with the ability to perform daily activities</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in the interference of pain with the ability to perform daily activities, measured using the pain dimension of the Endometriosis Health Profile-30 (EHP-30) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dyspareunia measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No analgesic use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at each scheduled assessment</time_frame>
    <description>Proportion of subjects reporting no analgesic use for endometriosis associated pain, during the preceding 4-week period at each scheduled assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No opiate use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at each scheduled assessment</time_frame>
    <description>Proportion of subjects reporting no opiate use for endometriosis associated pain, during the preceding 4-week period at each scheduled assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-back capsule (E2 1 mg / NETA 0.5 mg)</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule to match Add-back capsule</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The subject must have:&#xD;
&#xD;
          -  completed the 6-month treatment in the main study.&#xD;
&#xD;
          -  agree to continue to use only the analgesic rescue medication permitted by the&#xD;
             protocol during the Treatment and Follow-up Periods.&#xD;
&#xD;
          -  To continue to comply with the requirements of the study protocol for the duration of&#xD;
             the extension study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The subject will be excluded if she:&#xD;
&#xD;
          -  Is pregnant or breast feeding or is planning a pregnancy within the duration of the of&#xD;
             the study (including the Follow-up Period).&#xD;
&#xD;
          -  likely to require treatment during the study with any of the restricted medications&#xD;
&#xD;
          -  has any other clinically significant gynecologic condition identified during the main&#xD;
             study on transvaginal ultrasound (TVUS), on endometrial biopsy or at the manual breast&#xD;
             examination, which might interfere with the study efficacy and safety objectives.&#xD;
&#xD;
          -  met any of the main study discontinuation criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females Only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lecomte</last_name>
    <role>Study Director</role>
    <affiliation>ObsEva SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Choice Research, LLC/ ID # 609</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal Axon - Homestead, LLC/ ID # 620</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials/ ID # 612</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Specialty Research/ ID # 610</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's &amp; Family Care, LLC dba GTC Research/ ID # 608</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research / ID # 611</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research LLC/ ID# 602</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic/ ID # 624</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken / ID # 105</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sliven/ ID # 131</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Bratan Shukerov / ID #138</name>
      <address>
        <city>Smolyan</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Excelsior /ID # 135</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Practice for Specialized Medical Assistance in GINART/ ID # 132</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sofiamed&quot;/ ID # 133</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynekologicko - Porodnicka Ambulance/ ID # 162</name>
      <address>
        <city>Tábor</city>
        <zip>39003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynekologie MU Dr.Lubomir Mikulasek / ID # 160</name>
      <address>
        <city>Ujezd nad Lesy</city>
        <zip>19016</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur / ID # 206</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne/ ID # 402</name>
      <address>
        <city>Świdnik</city>
        <state>Lubelskie</state>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Klinika Ginekologiczno - Położnicza/ ID # 404</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Krzysztof Wilk/ ID # 411</name>
      <address>
        <city>Katowice</city>
        <zip>40-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research sp. Z o. O/ ID # 406</name>
      <address>
        <city>Katowice</city>
        <zip>40-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zrowotnej GynCentrum/ ID # 407</name>
      <address>
        <city>Katowice</city>
        <zip>40-851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotarski Jan Specjalistyczny Gabinet Ginekologiczno Polozniczy/ ID # 405</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Chodźki Lublin/ ID # 403</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITA LONGA Sp. z o.o./ ID # 408</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Ginekologii Endokrynologii i Medycyny Rozrodu &quot;Artemida&quot;/ ID # 409</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu/ ID # 410</name>
      <address>
        <city>Przemyśl</city>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401</name>
      <address>
        <city>Warsaw</city>
        <zip>02-929</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Medical Center SRL/ ID # 353</name>
      <address>
        <city>Bucharest</city>
        <zip>12071</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Nicolae Malaxa&quot;/ ID # 352</name>
      <address>
        <city>Bucharest</city>
        <zip>22448</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical EUROMED/ ID # 351</name>
      <address>
        <city>Bucuresti</city>
        <zip>20764</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sp Cl de Obstetrica si Ginecologie &quot;Prof. Dr. Panait Sirbu&quot;/ ID # 354</name>
      <address>
        <city>Bucuresti</city>
        <zip>60251</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gine Plus SRL Cluj- Napoca/ ID # 357</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400698</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrul Medical GALENUS/ ID # 355</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>540236</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofia/ ID # 304</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga/ ID # 303</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City clinical maternity hospital №1/ ID # 502</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk regional perinatal center, Family planning center/ ID # 506</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Maternity Hospital #6/ ID # 504</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center of LLC &quot;Medical Center &quot;Verum&quot;/ ID # 503</name>
      <address>
        <city>Kyiv</city>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Pediatrics Obstetrics and Gynecology/ ID # 508</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #9/ ID # 501</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Center of Reproductive and Perinatal Medicine/ ID # 509</name>
      <address>
        <city>Kyiv</city>
        <zip>04210</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ternopil' Communal City Hospital#2 / ID # 511</name>
      <address>
        <city>Ternopil</city>
        <zip>46400</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia City Clinical Hospital &quot;Center of Mother and the Child &quot;/ ID # 510</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21019</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Clinical Hospital/ ID # 505</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternity Hospital № 3/ ID # 507</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Dyschezia</keyword>
  <keyword>Non-menstrual pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

